Revolutionary treatment for psoriasis

Three per cent of the world’s population suffer from the skin condition known as psoriasis.

A Norwegian research-based company is close to developing a treatment that could help millions. The research may also prove beneficial in the treatment of other illnesses.

The psoriasis treatment consists of a compound which, when applied to the skin, is absorbed by skin cells much more naturally than most other ointments. It contains a synthesised molecule based on the fatty acid docosahexaenoic acid (DHA) which may prove effective in inhibiting chronic inflammation associated with psoriasis.

Clinical trials soon underway

Avexxin, a Trondheim-based company, is to begin clinical testing of the ointment in early 2013. If the results are positive, Avexxin may find itself on the cusp of an international breakthrough.

Successful tests of the psoriasis compound could also give an important boost to the pursuit of more comprehensive clinical trials to determine whether the technology can be applied to other chronic inflammatory conditions such as rheumatoid arthritis and nephritis, an inflammation in the kidneys.
Combining clinical phases 1 and 2A

Clinical trials often extend over a long period of time. The treatment must first be tested for toxicity on healthy volunteers. Subsequent trials must be carried out on real patients to ensure that the treatment has the desired effect. With an ointment such as this, which is to be applied externally, it is possible to combine trial phases 1 and 2A.

The Latest on: Immunotherapies

March 19, 2018 - SAN FRANCISCO—Researchers have developed a model to predict overall survival for people with advanced urothelial cancers treated with the immune checkpoint inhibitor atezolizumab. The model, which is based on six clinical factors, may help inform ... ...

March 19, 2018 - Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer. According to Mann, sipuleucel-T (Provenge) was far ahead of the curve when it was first developed ... ...

March 19, 2018 - Unum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14 ... ...

The Latest on: Fuel Cells

March 19, 2018 - ABB is working on fuel cell pilot projects with a number of major ship operators because it believes that hydrogen will be developed into an energy source for the maritime industry. Today, hydrogen trucks and buses are already operating and the rail ... ...

March 19, 2018 - Amid the buzz surrounding Class 8 heavy-duty trucks, let's remember that an electrified Class 8 solution is still in development. The two most common types of electric trucks being produced are all-battery electric and hydrogen-electric. Battery ... ...

March 18, 2018 - The fuel cell technology industry has witnessed very slow developments because of a lack of technology that is needed to process oxygen at a faster speed – a necessary key to cracking the code of fueling the cells efficiently. The engineers at Georgia . ...